Adult or pediatric (age 12 and older and weight 40kg or greater) with mild to moderate COVID-19 & high risk for progression to severe disease

Is Patient:
- Hospitalized for COVID-19 OR
- Requiring O₂ OR an increase in baseline home O₂ due to COVID-19

Symptom onset within the past 5-7 days?

Yes

No

Symptom onset within the past 10 days?

Yes

No

Treatment of symptoms, Management per NIH & CDC Guidelines

Does patient have severe renal impairment (eGFR <30mL/min) OR severed hepatic impairment (child-pugh class C)

Yes

No

Consider the following (symptoms within 10 days)¹:
- sotrovimab 500 mg IV within ASAP 10 days of symptom onset (sotrovimab EUA)
- Remdesivir 200mg IV x 1 dose on day 1, 100mg IV x 1 on days 2-3 begun ASAP and within 7 days of symptom onset

If none of the above therapeutics are available for patient treatment within 5 days of symptom onset and patient is age 18 or greater

Possibility of pregnancy, if applicable, is ruled out?

Yes

Consider molnupiravir
- Authorized only in patients ages 18 and older
- Within 5 days of symptom onset
- Molnupiravir 800mg by mouth every 12h for 5 days
- Prescribers must review and comply with the mandatory requirements outlined in the molnupiravir EUA

Limited use of bamlanivimab/etesevimab and REGEN-COV as they are not expected to be active against the Omicron variant²

¹Refer to the NIH COVID-19 Treatment Guidelines Panel’s Statement on the Use of Anti-SARS-CoV-2 Monoclonal Antibodies or Remdesivir for the Treatment of Covid-19 in Nonhospitalized patients when Omicron is the Predominant Circulating Variant; Remdesivir is only approved for hospitalized individuals with COVID-19. Outpatient treatment is based on information from the literature (Dec 22, 2021 Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients; DOI: 10.1056/NEJMoa2116846)

²COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies is authorized for the treatment of COVID-19 in patients with immunosuppressive disease in either the outpatient or inpatient setting (COVID-19 Convalescent Plasma EUA)

December 30, 2021